Health Economics›Colorectal cancer›Therapy for oligometastatic disease including perioperative therapy and hyperthermic intra-peritoneal chemotherapy

Therapy for oligometastatic disease including perioperative therapy and hyperthermic intra-peritoneal chemotherapy

Colorectal cancer · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
mFOLFOX6-B Variant #01	—	R 12 127	14d	~9.7 mo	~29.0 mo	~22	~R 266 798 PFS proxy · indirect	12
Intraperitoneal hyperthermic mitomycin Variant #01	—	R 5 668	—	—	~22.3 mo	—	—	1
Intraperitoneal hyperthermic oxaliplatin Variant #01	—	R 3 974	—	—	41.7 mo	—	—	1
FOLFIRI Variant #05	—	R 2 826	14d	—	15.0 mo	—	—	—
mFOLFOX6 Variant #02	—	R 2 466	14d	22.2 mo	—	49	R 120 857 PFS proxy	1
FOLFOX4 Variant #01	—	R 2 064	14d	—	—	—	—	1
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 1 629	14d	—	~20.7 mo	—	—	2
FULV Variant #01	—	R 1 466	35d	—	20.0 mo	—	—	—
Intraperitoneal 5-FU Variant #01	—	R 147	30d	—	~25.0 mo	—	—	1
Intrahepatic floxuridine N/A - secondary systemic drug	—	R 0	21d	—	—	—	—	—
Observation Partial	—	—	—	—	—	—	—	1
Intrahepatic floxuridine and IV 5-FU Partial	—	—	—	—	—	—	—	—

12 of 12 regimens shown